Waystar Reprices Term Loan, Boosts AI in Healthcare Payments with Iodine Acquisition
ByAinvest
Tuesday, Aug 12, 2025 5:09 pm ET1min read
WAY--
The company successfully reduced the interest rate on the term loan to adjusted SOFR +2.00%, a 25-basis-point reduction from prior terms. Additionally, Waystar will add $250 million of incremental term loans under the same terms, subject to the closing of the previously announced Iodine Software acquisition. This acquisition, valued at $1.25 billion, is part of Waystar's broader strategy to transform healthcare payments [2].
Waystar's stock price has been subject to fluctuations over the past few months. Insider sales and a recent filing for a $75.7 million stock sale have contributed to these movements. The company's stock options and common stock are also subject to a lock-up agreement ending on July 14, 2025, which may influence future stock price volatility [2].
Despite these market dynamics, Waystar's financial performance has been robust. The company reported strong Q2 2025 numbers, with revenue growing by 15.4% year-over-year to $270.65 million, and earnings per share (EPS) of $0.36, beating market estimates [2].
Waystar's mission-critical software is designed to simplify healthcare payments, enabling providers to prioritize patient care and optimize financial performance. The company serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list [1].
References:
[1] https://www.prnewswire.com/news-releases/waystar-enhances-financial-flexibility-with-term-loan-repricing-302528217.html
[2] https://seekingalpha.com/article/4811908-waystar-posts-impressive-q2-numbers-why-i-maintain-buy-rating
Waystar has repriced its term loan, although the terms of the deal are not disclosed. The company also recently acquired Iodine Software for $1.25 billion and reported Q2 adjusted earnings and revenue growth. Waystar's stock price has fluctuated over the past few months, with recent insider sales and a filing for a $75.7 million stock sale. The company's stock options and common stock are subject to a lock-up agreement ending on July 14, 2025.
Waystar (Nasdaq: WAY) has recently secured more favorable terms on its term loan, a move that underscores the company's strong financial position and robust cash flow generation. The repricing of the first lien term loan due October 2029 reflects high lender demand and positions Waystar to accelerate its growth strategy [1].The company successfully reduced the interest rate on the term loan to adjusted SOFR +2.00%, a 25-basis-point reduction from prior terms. Additionally, Waystar will add $250 million of incremental term loans under the same terms, subject to the closing of the previously announced Iodine Software acquisition. This acquisition, valued at $1.25 billion, is part of Waystar's broader strategy to transform healthcare payments [2].
Waystar's stock price has been subject to fluctuations over the past few months. Insider sales and a recent filing for a $75.7 million stock sale have contributed to these movements. The company's stock options and common stock are also subject to a lock-up agreement ending on July 14, 2025, which may influence future stock price volatility [2].
Despite these market dynamics, Waystar's financial performance has been robust. The company reported strong Q2 2025 numbers, with revenue growing by 15.4% year-over-year to $270.65 million, and earnings per share (EPS) of $0.36, beating market estimates [2].
Waystar's mission-critical software is designed to simplify healthcare payments, enabling providers to prioritize patient care and optimize financial performance. The company serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list [1].
References:
[1] https://www.prnewswire.com/news-releases/waystar-enhances-financial-flexibility-with-term-loan-repricing-302528217.html
[2] https://seekingalpha.com/article/4811908-waystar-posts-impressive-q2-numbers-why-i-maintain-buy-rating

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet